Servier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier’s Onco-hematology Portfolio
Discover our news
Servier receives a positive CHMP opinion for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients
Servier full year 2021/22 results confirm the transformation trajectory of the Group
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium
Real-World Analysis Suggests Pediatric-Inspired Regimens Lead to Higher Overall Survival in Adolescent and Young Adult Patients with Newly-Diagnosed Acute Lymphoblastic Leukemia
Servier Presents Patient Follow Up Data from the Phase 3 AGILE Study at ASH 2022
Servier Wins Reuters’ 2022 Patient Champion Award
New Data at ASH 2022 Bolster Servier’s Leadership in Hematology Research
Servier Pharmaceuticals Partners with Artists for Humanity